Sugi Predict

Sugi Predict / Targets / KCNN4

KCNN4

Intermediate conductance calcium-activated potassium channel protein 4 · O15554 · KCNN4 on Sugi Atlas →

28,389 patent compounds predicted against KCNN4, 8,834 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL986966 SCHEMBL986966 0.59 20/20
SCHEMBL985261 SCHEMBL985261 0.55 20/20
SCHEMBL986234 SCHEMBL986234 0.55 20/20
SCHEMBL983000 SCHEMBL983000 0.52 20/20
SCHEMBL983904 SCHEMBL983904 0.50 20/20
SCHEMBL984978 SCHEMBL984978 0.50 20/20
SCHEMBL985082 SCHEMBL985082 0.58 19/20
SCHEMBL988269 SCHEMBL988269 0.58 19/20
SCHEMBL986612 SCHEMBL986612 0.56 18/20
SCHEMBL986147 SCHEMBL986147 0.57 17/20
SCHEMBL987916 SCHEMBL987916 0.52 17/20
SCHEMBL812971 SCHEMBL812971 0.76 15/20
SCHEMBL985073 SCHEMBL985073 0.52 12/20
SCHEMBL362588 SCHEMBL362588 0.56 11/20
SCHEMBL830791 SCHEMBL830791 0.52 11/20
SCHEMBL626539 SCHEMBL626539 0.55 10/20
SCHEMBL705717 SCHEMBL705717 0.63 9/20
SCHEMBL1021928 SCHEMBL1021928 0.57 9/20
SCHEMBL898162 SCHEMBL898162 0.54 9/20
SCHEMBL976610 SCHEMBL976610 0.52 9/20

Clinical trials — most relevant to KCNN4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Characterisation of the Human Carboxylesterase 1 (CES1) Mutations in Thailand PHASE4COMPLETED
Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery PHASE4RECRUITING
Role of Intralipid in Management of Organophosphorus Poisoning PHASE2/PHASE3WITHDRAWN
Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation PHASE3COMPLETED
Diuretics, Hypertension, and Arrhythmias Clinical Trial PHASE3COMPLETED
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease PHASE2COMPLETED
4-Aminopyridine in Episodic Ataxia Type 2 PHASE2WITHDRAWN
A Clinical Study to Evaluate CAD-1883 in Essential Tremor PHASE2COMPLETED
Calcium Channel Blockade in Primary Aldosteronism PHASE2COMPLETED
Use of Antiarrhythmic Drugs in Pediatrics nanUNKNOWN
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY) nanCOMPLETED
The Use of Antiarrhythmic Drugs in Pediatrics nanUNKNOWN
Cryoballoon PVI With PWI Versus PVI Alone In Patients With PAF nanCOMPLETED
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism nanCOMPLETED
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development nanRECRUITING
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients. nanUNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Qatar Cardiovascular Biorepository of AF Patients nanUNKNOWN
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia nanUNKNOWN
Impact of Persistent Conductances on Motor Unit Firing in SCI nanUNKNOWN
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA) nanUNKNOWN
Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors nanUNKNOWN
Feasibility of Improving Risk Stratification in Brugada Syndrome nanCOMPLETED
Sodium Channel Splicing in Heart Failure Trial nanCOMPLETED
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction nanCOMPLETED
The Natural History of TRPV4 Neuropathy nanRECRUITING
A Single Center Prospective Study in an Estimated 570 Patients Who Underwent Genetic Screening at UZ Brussel in the Context of a Primary Cardiac Arrhythmia. Patients Showing a Variant Class 3,4 or 5 in SCN4A or CLCN1 Will Undergo a Clinical and Electrophysiological Review After IC. nanNOT_YET_RECRUITING
Effects of Photobiomodulation on the Innate Immune System of Neonates and Infants With Bronchiolitis nanUNKNOWN
The Energetic Origin of Neurodegeneration in MS nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a KCNN4 binder may also engage these)

ProteinNameSimilarity
O89109 — 1.000 O89109 →
Q9QYW1 — 0.997 Q9QYW1 →
P70606 — 0.972 P70606 →
Q9EQR3 — 0.971 Q9EQR3 →
KCNN1 Small conductance calcium-activated potassium channel protein 1 0.967 landscape →
TRPM4 Transient receptor potential cation channel subfamily M member 4 0.967 landscape →
Q7TN60 — 0.966 Q7TN60 →
Q9UIX4 — 0.966 Q9UIX4 →
A6NH21 — 0.965 A6NH21 →
SOAT2 Sterol O-acyltransferase 2 0.965 landscape →
GPAA1 GPI-anchor transamidase component GPAA1 0.965 landscape →
Q7Z403 — 0.965 Q7Z403 →
Q9ESQ5 — 0.964 Q9ESQ5 →
Q8TDN1 — 0.964 Q8TDN1 →
Q70J99 — 0.963 Q70J99 →
Q8IU68 — 0.963 Q8IU68 →
P70295 — 0.962 P70295 →
Q7TN37 — 0.962 Q7TN37 →
G3V8V5 — 0.962 G3V8V5 →
D4AD53 — 0.962 D4AD53 →
Q9WTK3 — 0.962 Q9WTK3 →
Q3UFQ8 — 0.962 Q3UFQ8 →
MAP4K2 Mitogen-activated protein kinase kinase kinase kinase 2 0.961 landscape →
B2RUP2 — 0.961 B2RUP2 →
Q7Z404 — 0.961 Q7Z404 →
Q0VF94 — 0.961 Q0VF94 →
O88454 — 0.961 O88454 →
Q5XHY1 — 0.961 Q5XHY1 →
Q8ND23 — 0.961 Q8ND23 →
Q5XK03 — 0.960 Q5XK03 →